Disclosures: Virginia Clark: Nothing to Disclose, Charlie Strange: Takeda: Grant/Research Support, Grifols: Grant/Research Support, Beam: Consultant, GlaxoSmithKline: Consultant, Krystal: Grant/Research Support, Vertex: Grant/Research Support, AlphaNet: Executive role, Pavel Strnad: Arrowhead Pharmaceuticals: Grant/Research Support, CSL Behring: Grant/Research Support, CSL Behring: Speaking and Teaching, BioMarin Pharmaceutical: Consultant, GSK: Consultant, Intellia: Consultant, Takeda Pharmaceuticals: Speaking and Teaching, Novo Nordisk: Consultant, Swedish Orphan Biovitrum: Consultant, Swedish Orphan Biovitrum: Speaking and Teaching, IPSEN: Consultant, James Hamilton: Nothing to Disclose, Rong Zhou: Nothing to Disclose, Thomas Schluep: Nothing to Disclose, Anne Wyman: Nothing to Disclose, Susana Gonzalez: Takeda Pharmaceutical: Employee, Yanwei Zhang: Nothing to Disclose, Rohit Loomba: Nothing to Disclose 2524 PREVALENCE ESTIMATES OF GENOTYPES ASSOCIATED WITH ALPHA-1 ANTITRYPSIN DEFICIENCY: A RETROSPECTIVE COHORT STUDY IN THE USA Grahame Evans 1 Xinruo Zhang 2 Jennifer Below 1 Kari North 2 May Hagiwara 3 Chitra Karki 3 Tami Nussbaum 3 Suna Park 3 Kaili Ren 3 Virginia Clark 4 , 1 Vanderbilt University, 2 University of North Carolina Chapel Hill, 3 Takeda Development Center Americas, Inc., 4 University of Florida Background: Pathogenic SERPINA1 variants cause alpha-1 antitrypsin deficiency (AATD)
Chronic mononucleosis syndrome
Therefore, collectively, these findings suggest that administering NAD + precursors prevents oxidative stress and mitochondrial dysfunction, and hence may be a useful therapeutic target for ALS
Additional information Hideyo Yoshida and Kiyotaka Y
concluded in 2024: We do not recommend the use of BPC-157 for sports performance and recovery because there are no randomized controlled trials in human subjects
